We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Sekisui Diagnostics UK Ltd.

Download Mobile App




Cervical Cancer Screening Rates Declining in Younger Women

By HospiMedica International staff writers
Posted on 21 Jan 2019
Print article
Image: A disparity exists between self-reported and actual CVC screening (Photo courtesy of Corbis).
Image: A disparity exists between self-reported and actual CVC screening (Photo courtesy of Corbis).
A new study concludes that the percentage of women screened for cervical cancer (CVC) may be far lower than self-reported data suggests.

Researchers at the Mayo Clinic (Rochester, MN, USA) conducted an epidemiologic study in order to assess implementation of the 2012 U.S. CVC screening recommendations, which recommend Papanicolaou (PAP) testing every three years for women 21–65 years of age, or PAP–human papillomavirus (PAP-HPV) co-testing at five year intervals for women 30–65 years of age. A secondary aim was to assess sociodemographic factors correlating with screening. The study population included women 16 years and older living in Olmsted County (MN, USA).

Rochester Epidemiology Project data was collected yearly from 2005 (47,203 participants) through 2016 (49,510 participants). Significant declines in PAP completion rates over time were observed in all age groups, including an unexpected decline in women 21- 29 year of age. Coincident with decreasing PAP screening rates, PAP-HPV co-testing significantly increased among women age 30–65 years, from 10% in 2007 to 60.8% in 2016, with 64.6% of women 30-65-years of age up to date with CVC screening. The study was published on January 9, 2018, in the Journal of Women's Health.

“These cervical cancer rates are unacceptably low. Routine screening every three years with a PAP test or every five years with a PAP-HPV co-test ensures precancerous changes are caught early and may be followed more closely or treated,” said lead author Kathy MacLaughlin, MD. “African-American women were 50% less likely to be up-to-date on CVC screening than white woman, and Asian women were nearly 30% less likely to be current on screening. These racial disparities are especially concerning.”

PAP-HPV co-testing has a lower false negative rate than PAP testing alone, as it reduces the likelihood of missing an anomaly and improves detection of glandular cell abnormalities. Despite these benefits, the study results indicate that actual screening rates are substantially lower than the 81% compliance rate self-reported in the 2015 National Health Interview Survey.

Related Links:
Mayo Clinic

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Mechanical Baby Scale
seca 725

Print article

Channels

Surgical Techniques

view channel
Image: LUMISIGHT and Lumicell DVS offer 84% diagnostic accuracy in detecting residual cancer (Photo courtesy of Lumicell)

Cutting-Edge Imaging Platform Detects Residual Breast Cancer Missed During Lumpectomy Surgery

Breast cancer is becoming increasingly common, with statistics indicating that 1 in 8 women will develop the disease in their lifetime. Lumpectomy remains the predominant surgical intervention for treating... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The Quantra Hemostasis System has received US FDA special 510(k) clearance for use with its Quantra QStat Cartridge (Photo courtesy of HemoSonics)

Critical Bleeding Management System to Help Hospitals Further Standardize Viscoelastic Testing

Surgical procedures are often accompanied by significant blood loss and the subsequent high likelihood of the need for allogeneic blood transfusions. These transfusions, while critical, are linked to various... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.